flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk 🚨 Journal Club: FLOW Trial – Kidney Outcomes With Glucagon-Like Peptide-1

J.FinestraT

K., Murugesan S., Kunjiappan S

and (4) ischemia resulting from transient four-vessel occlusion ( 125 I]-AngIV have been localized in structures known to mediate cognitive processing including the neocortex, hippocampus, and basal nucleus of Meynert (56, 75)

However, compared with the intensive mechanistic studies of carnitine in mammals, the majority of the studies of carnitine in fish have only focused on the effects of carnitine on the fishs growth and body composition, whereas studies on the systemic regulation of nutritional metabolism by carnitine in fish, and the underlying mechanisms, are lacking